Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | TP53 | P04637 | 6/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17385041 | 0.90 | MAPT (0.52) | MAPTTP53POLBSMN1; SMN2RAB9A | |
| SCHEMBL17385379 | 0.88 | TP53 (0.52) | MAPTTP53SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL17385404 | 0.88 | TP53 (0.50) | MAPTTP53POLBSMN1; SMN2RAB9A | |
| SCHEMBL17385433 | 0.87 | TP53 (0.54) | MAPTTP53SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL17385376 | 0.86 | MAPT (0.47) | MAPTTP53POLBPIN1 | |
| SCHEMBL17385371 | 0.86 | HRH3 (0.51) | MAPTTP53POLBSMN1; SMN2RAB9A | |
| SCHEMBL17385035 | 0.85 | PIN1 (0.50) | MAPTTP53POLBSMN1; SMN2RAB9A | |
| SCHEMBL17385402 | 0.84 | PIN1 (0.46) | MAPTTP53SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL17385355 | 0.84 | SMN1; SMN2 (0.51) | MAPTTP53SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL17385414 | 0.83 | HPGD (0.48) | MAPTTP53SMN1; SMN2PIN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153756-A1 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2022-05-19 | — | — | US | disclosed |
| EP-3157904-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2020-11-18 | — | — | EP | disclosed |
| WO-2015193506-A1 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153756-A1 | ANTI-INFECTIVE COMPOUNDS | RABGGTB, ELANE, SERPINB1 | MAPT 2660/4885TP53 2233/4885POLB 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.